Pfizer Touts Relpax Efficacy Versus Excedrin Migraine In Study
This article was originally published in The Tan Sheet
Executive Summary
Pfizer is targeting the competition from OTC analgesics in a recently published study on the superior efficacy of its Relpax (eletriptan) versus Bristol-Myers Squibb's Excedrin Migraine